UA126890C2 - Вакцина проти вірусу імунодефіциту людини (віл), що містить один або більше епісенсусних (episensus) для популяції антигенів - Google Patents
Вакцина проти вірусу імунодефіциту людини (віл), що містить один або більше епісенсусних (episensus) для популяції антигенів Download PDFInfo
- Publication number
- UA126890C2 UA126890C2 UAA201704021A UAA201704021A UA126890C2 UA 126890 C2 UA126890 C2 UA 126890C2 UA A201704021 A UAA201704021 A UA A201704021A UA A201704021 A UAA201704021 A UA A201704021A UA 126890 C2 UA126890 C2 UA 126890C2
- Authority
- UA
- Ukraine
- Prior art keywords
- guz
- rgo
- sip
- hiv
- siu
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/867—Retroviral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16141—Use of virus, viral particle or viral elements as a vector
- C12N2710/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462059497P | 2014-10-03 | 2014-10-03 | |
| US201462059506P | 2014-10-03 | 2014-10-03 | |
| PCT/US2015/054067 WO2016054654A1 (en) | 2014-10-03 | 2015-10-05 | Hiv vaccines comprising one or more population episensus antigens |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA126890C2 true UA126890C2 (uk) | 2023-02-22 |
Family
ID=55631703
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA201704021A UA126890C2 (uk) | 2014-10-03 | 2015-10-05 | Вакцина проти вірусу імунодефіциту людини (віл), що містить один або більше епісенсусних (episensus) для популяції антигенів |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US10894078B2 (https=) |
| EP (1) | EP3200878B1 (https=) |
| JP (3) | JP2017531693A (https=) |
| KR (1) | KR102633096B1 (https=) |
| CN (1) | CN108064181A (https=) |
| AU (2) | AU2015327797A1 (https=) |
| CA (1) | CA2963573C (https=) |
| EA (1) | EA201790680A1 (https=) |
| HK (1) | HK1254806A1 (https=) |
| IL (1) | IL251469B2 (https=) |
| MA (1) | MA40783A (https=) |
| MX (3) | MX391149B (https=) |
| SG (1) | SG11201702729YA (https=) |
| UA (1) | UA126890C2 (https=) |
| WO (1) | WO2016054654A1 (https=) |
| ZA (1) | ZA202206809B (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA40783A (fr) | 2014-10-03 | 2017-08-08 | Los Alamos Nat Security Llc | Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population |
| EP3319631A4 (en) | 2015-07-08 | 2019-01-09 | American Gene Technologies International Inc. | HIV PREMUNICATION AND IMMUNOTHERAPY |
| WO2017139065A1 (en) | 2016-02-08 | 2017-08-17 | American Gene Technologies International Inc. | Hiv vaccination and immunotherapy |
| AU2017292582C1 (en) | 2016-07-08 | 2021-11-11 | American Gene Technologies International Inc. | HIV pre-immunization and immunotherapy |
| WO2020243485A1 (en) * | 2019-05-29 | 2020-12-03 | Massachusetts Institute Of Technology | Hiv-1 specific immunogen compositions and methods of use |
| KR20240137107A (ko) | 2019-07-16 | 2024-09-19 | 길리애드 사이언시즈, 인코포레이티드 | Hiv 백신, 및 이의 제조 및 사용 방법 |
| MX2022002270A (es) | 2019-08-29 | 2022-03-22 | Vir Biotechnology Inc | Vacunas contra el virus de la hepatitis b. |
| US12053517B2 (en) * | 2021-01-14 | 2024-08-06 | Gilead Sciences, Inc. | HIV vaccines and methods of using |
| JP2024534189A (ja) | 2021-08-31 | 2024-09-18 | ヴィア・バイオテクノロジー・インコーポレイテッド | 組換えｈｃｍｖベクター及びその使用 |
| TW202436326A (zh) * | 2023-02-13 | 2024-09-16 | 長怡 王 | 包含hiv th/ctl 抗原決定位胜肽的疫苗用於預防及治療hiv感染及aids患者 |
| CN116524994B (zh) * | 2023-02-20 | 2026-01-30 | 中国科学院天津工业生物技术研究所 | 一种基于贪婪算法的菌株构建排程设计方法 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI116851B (fi) * | 2001-05-03 | 2006-03-15 | Fit Biotech Oyj Plc | Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita |
| MXPA04002631A (es) * | 2001-09-20 | 2004-07-08 | Glaxo Group Ltd | Vacunas de adn optimizadas por codon gag-vih. |
| AUPR842501A0 (en) | 2001-10-23 | 2001-11-15 | Epipop Pty Ltd | A method for identification and development of therapeutic agents |
| US20030190308A1 (en) * | 2002-03-19 | 2003-10-09 | Braun Ralph P. | Adjuvant |
| GB0225788D0 (en) * | 2002-11-05 | 2002-12-11 | Glaxo Group Ltd | Vaccine |
| US20070054262A1 (en) * | 2003-03-28 | 2007-03-08 | Baker Denise M | Methods of identifying optimal variants of peptide epitopes |
| AU2011203095A1 (en) | 2003-09-17 | 2011-07-21 | Duke University | Consensus/Ancestral Immunogens |
| BRPI0414443A (pt) * | 2003-09-17 | 2006-11-21 | Univ Duke | imunógenos consensuais/ancestrais |
| EA012066B1 (ru) | 2003-10-10 | 2009-08-28 | Паудерджект Вэксинс, Инк. | Способ, вызывающий т-клеточный ответ |
| EP2497831B1 (en) | 2004-05-25 | 2014-07-16 | Oregon Health and Science University | TB vaccination using HCMV-based vaccine vectors |
| CN101969996A (zh) * | 2005-08-23 | 2011-02-09 | 加利福尼亚大学董事会 | 多价疫苗 |
| CA3057039C (en) | 2006-07-28 | 2023-02-28 | The Trustees Of The University Of Pennsylvania | Hiv consensus envelope sequences and methods for using same |
| US20110123485A1 (en) * | 2007-03-27 | 2011-05-26 | President And Fellows Of Harvard College | Viral vectors for delivering vaccines for hiv and other infectious diseases |
| WO2008121282A2 (en) * | 2007-03-30 | 2008-10-09 | Merck & Co., Inc. | Broadly representative antigen sequences and method for selection |
| NZ602504A (en) | 2008-11-18 | 2014-01-31 | Beth Israel Hospital | Antiviral vaccines with improved cellular immunogenicity |
| AU2010305030A1 (en) * | 2009-10-08 | 2012-05-10 | Bavarian Nordic A/S | Generation of a broad T-cell response in humans against HIV |
| AU2011230619C1 (en) | 2010-03-25 | 2016-06-23 | Oregon Health & Science University | CMV glycoproteins and recombinant vectors |
| TR201802741T4 (tr) * | 2010-05-14 | 2018-03-21 | Univ Oregon Health & Science | Rekombinant hcmv ve rhcmv vektörleri ve bunların kullanımları. |
| US8557787B2 (en) | 2011-05-13 | 2013-10-15 | The Board Of Trustees Of The Leland Stanford Junior University | Diagnostic, prognostic and therapeutic uses of long non-coding RNAs for cancer and regenerative medicine |
| HUE037408T2 (hu) | 2011-06-10 | 2018-08-28 | Univ Oregon Health & Science | CMV glikoproteinek és rekombináns vektorok |
| EP2620446A1 (en) | 2012-01-27 | 2013-07-31 | Laboratorios Del Dr. Esteve, S.A. | Immunogens for HIV vaccination |
| EP2820035B1 (en) | 2012-03-02 | 2019-01-09 | The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services | Method of altering the immundominance hierarchy of hiv gag by dna vaccine expressing conserved regions |
| SG10201705880QA (en) * | 2013-01-07 | 2017-08-30 | Beth Israel Deaconess Medical Ct Inc | Stabilized human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same |
| DK2964769T3 (en) | 2013-03-05 | 2018-12-10 | Univ Oregon Health & Science | Cytomegalovirus vectors enabling control of T cell targeting |
| CA2941116A1 (en) | 2014-02-28 | 2015-09-03 | Janssen Vaccines & Prevention B.V. | Replicating recombinant adenovirus vectors, compositions, and methods of use thereof |
| CN113528466B (zh) | 2014-07-16 | 2024-12-24 | 俄勒冈健康与科学大学 | 包含外源抗原的人巨细胞病毒 |
| CN106999571B (zh) | 2014-09-26 | 2020-10-02 | 贝斯以色列护理医疗中心有限公司 | 诱导针对人免疫缺陷病毒感染的保护性免疫性的方法和组合物 |
| MA40783A (fr) | 2014-10-03 | 2017-08-08 | Los Alamos Nat Security Llc | Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population |
| DK3584252T3 (da) | 2015-12-15 | 2021-11-15 | Janssen Vaccines & Prevention Bv | Human immundefektvirus-antigener, -vektorer, -sammensætninger og fremgangsmåder til anvendelse deraf |
-
2015
- 2015-10-04 MA MA040783A patent/MA40783A/fr unknown
- 2015-10-05 KR KR1020177012171A patent/KR102633096B1/ko active Active
- 2015-10-05 SG SG11201702729YA patent/SG11201702729YA/en unknown
- 2015-10-05 EP EP15847978.2A patent/EP3200878B1/en active Active
- 2015-10-05 UA UAA201704021A patent/UA126890C2/uk unknown
- 2015-10-05 WO PCT/US2015/054067 patent/WO2016054654A1/en not_active Ceased
- 2015-10-05 EA EA201790680A patent/EA201790680A1/ru unknown
- 2015-10-05 JP JP2017538177A patent/JP2017531693A/ja active Pending
- 2015-10-05 CN CN201580063643.3A patent/CN108064181A/zh active Pending
- 2015-10-05 HK HK18113892.2A patent/HK1254806A1/zh unknown
- 2015-10-05 CA CA2963573A patent/CA2963573C/en active Active
- 2015-10-05 IL IL251469A patent/IL251469B2/en unknown
- 2015-10-05 MX MX2017004275A patent/MX391149B/es unknown
- 2015-10-05 US US15/516,491 patent/US10894078B2/en active Active
- 2015-10-05 AU AU2015327797A patent/AU2015327797A1/en not_active Abandoned
-
2017
- 2017-03-31 MX MX2022003664A patent/MX2022003664A/es unknown
- 2017-03-31 MX MX2022003663A patent/MX2022003663A/es unknown
-
2020
- 2020-08-31 US US17/008,335 patent/US11554168B2/en active Active
- 2020-08-31 US US17/008,289 patent/US11628215B2/en active Active
- 2020-10-09 JP JP2020170852A patent/JP7212020B2/ja active Active
-
2021
- 2021-08-19 AU AU2021218141A patent/AU2021218141B2/en active Active
-
2022
- 2022-06-20 ZA ZA2022/06809A patent/ZA202206809B/en unknown
-
2023
- 2023-01-12 JP JP2023003194A patent/JP7441340B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA126890C2 (uk) | Вакцина проти вірусу імунодефіциту людини (віл), що містить один або більше епісенсусних (episensus) для популяції антигенів | |
| Xia et al. | A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike | |
| Duehr et al. | Neutralizing monoclonal antibodies against the Gn and the Gc of the Andes virus glycoprotein spike complex protect from virus challenge in a preclinical hamster model | |
| EA023888B1 (ru) | Репликационно-дефектные вакцины и вакцинные векторы против флавивирусов | |
| Stucker et al. | The role of evolutionary intermediates in the host adaptation of canine parvovirus | |
| EA015907B1 (ru) | Рекомбинантный флавивирус и его применение | |
| UA113496C2 (xx) | Вектор і спосіб підвищення стійкості до інфекції, що викликається campylobacter | |
| Hofer et al. | Understanding and improving vaccine efficacy in older adults | |
| Chehelgerdi et al. | Immunoinformatic prediction of potential immunodominant epitopes from cagW in order to investigate protection against Helicobacter pylori infection based on experimental consequences | |
| Zhang et al. | Identification of b-cell epitopes on capsid protein reveals two potential neutralization mechanisms in red-spotted grouper nervous necrosis virus | |
| US20080207875A1 (en) | Preventive and Therapeutic Use of polypeptides from African Swine Virus as Vaccines | |
| Acciani et al. | Uncovering the features of Measles-targeting human antibodies elicited by the MMR vaccine | |
| Zhang et al. | Structural and functional characteristics of SARS-CoV-2 Omicron subvariant BA. 2 spike | |
| CN117321069A (zh) | 基于减毒呼肠孤病毒的疫苗组合物及其用途 | |
| EA040402B1 (ru) | Вакцины против вируса иммунодефицита человека (вич), содержащие один или более эписенсусных (episensus) антигенов для популяции | |
| HK1241309A1 (en) | Hiv vaccines comprising one or more population episensus antigens | |
| Shabaltiy | Predicted Structure and Analysis of the Glycoprotein from SARS-CoV-2 Variants of Interest | |
| HK1241309B (en) | Hiv vaccines comprising one or more population episensus antigens | |
| Kumar et al. | Non-Synonymous Mutation analysis in SARS-CoV-2 variants isolated from Humans and Prediction of Conserved Linear Antibody Epitopes for Use in Country-wise Epitope-based Vaccine Development | |
| Javanmardi | Engineering programmable platforms in mammalian cells for the rapid characterization of viral proteins | |
| Perrone et al. | BIOLOGICAL PROSTHESES IN PATIENTS YOUNGER THAN 65 YEARS OLD: A PROPENSITY-SCORE MATCHING ANALYSIS BETWEEN THE TWO MOST IMPLANTED BOVINE PERICARDIAL VALVES. | |
| Sur et al. | In silico immunoinformatics based prediction and designing of multi-epitope construct against human rhinovirus C | |
| Pérez | The impact of vaccination against rotavirus on viral faecal shedding, genetic stability and mucosal immune response in a cohort of infants in the UK | |
| Chang | Genome Packaging in Single-Stranded RNA Viruses | |
| BR122021016789B1 (pt) | Vacinas contra hiv-1 compreendendo um ou mais antígenos epissenso de população, usos das mesmas para proteger um indivíduo de uma infecção por hiv-1, tratar hiv-1 e induzir uma resposta de células t de memória efetoras, bem como polipeptídeo e método para projetar e produzir as ditas vacinas |